Methods for reprogramming somatic cells

Patent metadata

Field	Value
Publication number	US-9670464-B2
Application number	US-201514923321-A
Country	US
Kind code	B2
Filing date	Oct 26, 2015
Priority date	Nov 26, 2003
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

First claim

What is claimed is:

1. A composition comprising:
a polynucleic acid encoding an Oct4 protein, and
a polynucleic acid encoding a Sox2 or a Nanog protein;
wherein one or both of the polynucleic acids is operatively linked to at least one heterologous regulatory sequence.

2. The composition of claim 1 , further comprising a candidate agent of interest with respect to its potential to reprogram a somatic cell.

3. The composition of claim 2 , wherein the candidate agent of interest is a DNA methylation inhibitor, a histone deacetylase inhibitor or PD098059.

4. A composition comprising an isolated somatic cell that comprises an exogenously introduced polynucleic acid encoding Oct4 protein, and an exogenously introduced polynucleic acid encoding Sox2 or Nanog protein.

5. The composition of claim 4 , wherein the exogenous polynucleic acids increase Oct4 expression in the isolated somatic cell.

6. The composition of claim 4 , wherein the isolated somatic cell is a mammalian cell.

7. The composition of claim 4 , wherein the isolated somatic cell is a human cell or a mouse cell.

8. The composition of claim 4 , wherein the isolated somatic cell is an adult stem cell.

9. The composition of claim 8 , wherein the adult stem cell is selected from the group consisting of: a hematopoietic stem cell, a neural stem cell, and a mesenchymal stem cell.

10. The composition of claim 4 , comprising a candidate agent of interest with respect to its potential to reprogram a somatic cell.

11. The composition of claim 10 , wherein the candidate agent of interest is a DNA methylation inhibitor, a histone deacetylase inhibitor or PD098059.

12. A composition comprising one or more recombinant expression cassettes encoding: a polynucleic acid encoding an Oct4 protein, and a polynucleic acid encoding a Sox2 or a Nanog protein, wherein the polynucleic acids are operably linked to a heterologous promoter.

13. The composition of claim 12 , further comprising a candidate agent of interest with respect to its potential to reprogram a somatic cell.

14. The composition of claim 13 , wherein the candidate agent of interest is a DNA methylation inhibitor, a histone deacetylase inhibitor or PD098059.

Assignees

• Whitehead Inst Biomedical Res

Inventors

• Jaenisch Rudolf
• Hochedlinger Konrad

Classifications

• C12N15/85

  for animal cells · CPC title

• A01K2217/05

  Animals comprising random inserted nucleic acids (transgenic) · CPC title

• C12N2501/602

  Sox-2 · CPC title

• C12N5/0696 Primary

  Artificially induced pluripotent stem cells, e.g. iPS · CPC title

• A01K67/0273 Primary

  Cloned vertebrates · CPC title